Teva Pharmaceutical Industries Limited reported $14.1B of revenue over the trailing twelve months, −15% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $14.1B (to Q2 2026). Net income: $706M, trailing twelve months to Q2 2026. Free cash flow: $1.35B, trailing twelve months to Q2 2026. Operating margin: 13%, trailing twelve months to Q2 2026.

TEVATeva Pharmaceutical Industries Limited

Healthcare

$41.14+118% 1Y

$41.14

$18.3452 weeks$41.14

Latest close: a new 52-week highOct 12, 2026what changed →

TEVA as reported

Teva Pharmaceutical Industries Limited reported $14.1B of revenue over the trailing twelve months, −15% on the year before. 11 reported series are charted on this page, each one as filed.

$14.1B

Revenue, trailing twelve months · to Q2 2026 · −15% against the twelve months before

Net income: $706M
Net income · −547% year on year · trailing twelve months to Q2 2026
Free cash flow: $1.35B
Free cash flow · +51% year on year · trailing twelve months to Q2 2026
Operating margin: 13%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for TEVA, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$14.1B	−15%	Q2 2026
Net income	$706M	−547%	Q2 2026
EPS	$0.60	−475%	Q2 2026
Gross margin	82%	n/a	Q2 2026
Operating margin	13%	n/a	Q2 2026
Net margin	9.3%	n/a	Q2 2026
ROE	14%	n/a	Q2 2026
ROA	2.7%	n/a	Q2 2026
ROIC	24%	n/a	Q2 2026
Free cash flow	$1.35B	+51%	Q2 2026
P/E	68.6	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.